 |
|
 |
|
| |
Moving Stem Cell Research Forward: The Need for Standardization
Event Date: January 28, 2010 11 a.m. Eastern, 8 a.m. Pacific, 4 p.m. GMT
Brought to you by the Science/AAAS Business Office
|
| |
|
|
| |
Real Player | | | Real Media Video (56k/150k) | | |
Windows Media Player | | | Windows Media Video (56k/150k) |
|
| |
|
|
| |
Stem cell research has the potential to significantly impact a broad range of life science endeavors, ranging from improved drug discovery processes to revolutionary new therapeutics. The ability to control differentiation of stem cells into specialized cell types with high yield and precision is a key success factor that will determine the ultimate utility of such research. However, researchers are facing significant challenges in these efforts because stem cells are difficult to handle and there are very few automated or standardized tools available in this relatively new field. In this hour, we will hear from three panelists on the need for, and progress towards, a new level of standardization and automation in the management and handling of stem cell cultures and their differentiated progeny.
Webinar viewers will:
- learn about common hurdles to be overcome when culturing stem cells
- obtain guidance on best practices for handling and manipulating stem cells
- hear about the latest technologies for standardizing and automating stem cell culture
- have the chance to put their questions to the panelists live!
|
|
| |
Speakers:
 |
Ron McKay, Ph.D.
National Institutes of Health
Bethesda, MD
Dr. Ronald D.G. McKay received a B.Sc. degree in 1971, and his Ph.D. in 1974 from the University of Edinburgh in the United Kingdom, where he studied under the tutelage of Edwin Southern, examining DNA organization and chromosome structure. He received postdoctoral training at the University of Oxford working with Walter Bodner, examining restriction fragment length polymorphism (RFLPs). In 1978, he became a senior staff investigator at Cold Spring Harbor Laboratory, concentrating on two areas: the interaction of SV40 T-antigen with the specific binding site at the viral origin of replication and the molecular organization of the nervous system. Joining the Massachusetts Institute of Technology faculty in 1984, Dr. McKay continued to examine different aspects of neuronal organization in the nervous system. In 1993, he came to the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health in Bethesda, Maryland as Chief of the Laboratory of Molecular Biology. His laboratory currently studies contact-dependent and soluble signals that control the proliferation and differentiation of stem cells.
|
 |
Amy Wagers, Ph.D.
Harvard University
Boston, MA
Dr. Amy J. Wagers completed her undergraduate degree in biological sciences at Northwestern University in Evanston, Illinois, followed by a Ph.D. at Northwestern Medical School in the area of immunology and microbial pathogenesis. She is currently an associate professor in the Department of Stem Cell and Regenerative Biology at Harvard University in Boston, Massachusetts, an investigator in the Section on Developmental and Stem Cell Biology at Joslin Diabetes Center, and a principal faculty member of the Harvard Stem Cell Institute in Cambridge, Massachusetts. Dr. Wagers directs a research laboratory that focuses on defining the factors and mechanisms regulating the migration, expansion, and regenerative potential of blood-forming and muscle-forming stem cells. Her lab employs sensitive cell sorting approaches for direct assessment of stem cell phenotype and function, and to develop surrogate in vitro assays that faithfully reflect stem cell potential. Dr. Wagers is a recipient of the Burroughs Wellcome Fund Career Award, the W.M. Keck Foundation Distinguished Young Scholar Award, the NIH Innovator Award, and an Early Career Award from the Howard Hughes Medical Institute.
|
 |
Mark D. Noble, Ph.D.
University of Rochester Medical Center
Rochester, NY
Dr. Mark Noble obtained his Ph.D. from Stanford University before carrying out his postdoctoral training at University College London in the United Kingdom. He is one of the pioneers of stem cell research with contributions dating back to 1983 when, as a member of a team of researchers in London, he co-discovered the first precursor cell isolated from the central nervous system (CNS). His laboratory was then the first to identify means of growing these cells in tissue culture, means of enabling expansion sufficient for carrying out repair, and the first to the obtain cell repair in the damaged central nervous system through transplantation of purified populations of precursor cells. Dr. Noble and his associates currently work in a range of areas, broadly related to signaling within the CNS in normal and diseased states (including cancer), and damage and repair of CNS injury. He currently holds professorships in genetics, neurology and neurobiology, and anatomy at University of Rochester School of Medicine, New York, and is Director of the University of Rochester Stem Cell and Regenerative Medicine Institute and Co-Director of the New York State Center of Research Excellence for Spinal Injury Research. He is an inventor on 11 filed or pending patents and has consulted for multiple pharmaceutical and biotechnology companies. Dr. Noble also was a member of the founding scientific advisory board of Acorda Therapeutics, Inc., a biotechnology company focused on the treatment of neurological disease. He is co-author of over 140 scientific publications.
|
|
|
| |
Moderator: Sean Sanders, Ph.D., Commercial Editor, Science/AAAS
 |
Sean Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Worldwide Commercial Editor for the journal Science and Program Director for Outreach.
|
|
|
|
| |
___________________________________________________________________________________________________
|
 |
|
| |
For the best experience we recommend you use Internet Explorer 6 (IE6) or higher on a Windows-based PC to view this webinar. Please ensure that you are using a computer with a stable internet connection and good bandwidth. To ensure the best possible performance of the webinar we recommend that you avoid using a dial-up connection. Note: please confirm the start time of the webinar in your time zone. A free time zone converter is available at www.timeanddate.com/worldclock/converter.html
|
| |
Test Your System
|
| | Help |
| |
Download Real Player
|
| |
Download Silverlight
|
| |
|
|
|